

Stephens Biotechnology Virtual Fireside Chats 2025

NOVEMBER 3-7, 2025



Presenting Companies:

Actinium Pharmaceuticals Inc. (ATNM)

- Sandesh Seth, CEO & Chairman of the Board

ADC Therapeutics SA (ADCT)

- Ameet Mallik, CEO

Biotheryx, Inc. (Private)

- Leah Fung, Ph.D., CEO

Candel Therapeutics, Inc. (CADL)

- Paul Peter Tak, M.D., Ph.D., FMedSci, President & CEO

Cullgen Inc. (Private)

- Ying Luo, Ph.D., Chairman & President
- Jialiang Wang, Ph.D., EVP - Operations

Delcath Systems Inc. (DCTH)

- Gerard Michel, CEO

Exelixis Inc. (EXEL)

- Michael Morrissey, Ph.D., President & CEO

Fennec Pharmaceuticals, Inc. (FENC)

- Robert Andrade, CFO

Immunome, Inc. (IMNM)

- Max Rosett, CFO

INOVIO (INO)

- Jacqueline Shea, Ph.D., President & CEO
- Michael Sumner, MB BS, MBA, Chief Medical Officer

Kymera Therapeutics, Inc. (KYMR)

- Jared Gollob, MD, Chief Medical Officer
- Bruce Jacobs, CFA, MBA, CFO

Pyxis Oncology, Inc. (PYXS)

- Lara Sullivan, MD, President, CEO & Chief Medical Officer

SEED Therapeutics, Inc. (Private)

- Lan Huang, Ph.D., Co-Founder, CEO & Chairman

Sensei Biotherapeutics Inc. (SNSE)

- John K. Celebi, MBA, President & CEO
- Ron Weitzman, MD, FACP, Chief Medical Officer

Additional Details:

There will be a virtual panel discussion with management team members from public and private Targeted Protein Degradator (TPD) Companies to discuss the advancements to-date and their take on the future potential of TPDs on November 5, 2025 at 1:00pm ET.



Space will be limited. Meeting times and itinerary subject to change. To join the meetings or to obtain more information, please contact your Stephens sales representative.

Virtual Meetings Host

Sudan Loganathan, PhD
Research Analyst
Biotechnology
(212) 891-1762
sudan.loganathan@stephens.com

Stephens

INSTITUTIONAL EQUITIES & RESEARCH

stephens.com

f in X 800-643-9691

© 2025 STEPHENS INC., MEMBER NYSE, SIPC | 111 CENTER STREET, LITTLE ROCK, AR 72201

[UNSUBSCRIBE](#) [EMAIL PREFERENCES](#) [VIEW ONLINE](#)

This announcement has been prepared solely for informative purposes as of its stated date and is not a solicitation, or an offer, to buy or sell any security. It does not purport to be a complete description of the securities, markets or developments referred to in the material. The research analyst principally responsible for preparation of this announcement has received compensation that is based on the firm's overall revenue which includes investment banking revenue. To access current disclosures for the companies in this announcement, clients should refer to <http://disclosure.stephens.com/webdata/Discls.asp?c=1> or contact your Stephens Inc. representative for additional information. Please also note that the announcement may include one or more links to external or third-party websites. Stephens Inc. has not independently verified the information contained on such websites and can provide no assurance as to the reliability of such information, and there can be no assurance that any opinions expressed on such websites reflect the opinions of Stephens Inc. or its management. Artificial intelligence tools may have been used in the preparation of this material, including assisting in data analysis, pattern recognition, and content drafting for research material. Additional information available upon request.